CI

At a glance

ClinicalIndex Comparison Record
Phase 1Completed· 18 enrolled
Drug / intervention
BIA 2-093drug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02288312
NCT02288312Phase 1Completed
CompareCT.gov

Food Effect and Dosage Form Proportionality Study of Eslicarbazepine Acetate Market Formulation in Healthy Volunteers

Bial - Portela C S.A.·interventional·Posted Nov 11, 2014·Updated Jan 8, 2015

In Brief

A Phase 1 clinical trial evaluating BIA 2-093 for Epilepsy. Completed, enrolled 18 participants.

Detailed Summary

Single-centre, open-label, randomised, gender-balanced, 3-way crossover, 3-period, 3-sequence study in 18 healthy male and female subjects.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsEpilepsy
Countries--
Collaborators--

Timeline

Phase 1CompletedFinished
200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedNov 11, 2014
Enrollment StartMay 1, 2007
Primary CompletionJul 1, 2007
TodayJul 2, 2026
Enrollment to primary: 2 monthsPosted 11.6 years ago

Interventions

BIA 2-093drug